Rivastigmine for the treatment of dementia associated with Parkinson's disease

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 6, 2007, Pages 775-783

  Reingold, Jennifer L ^a   Morgan, John C ^a   Sethi, Kapil D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cholinesterase inhibitor; Dementia; Parkinson's disease; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; BRADYCARDIA; CLINICAL TRIAL; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; HALLUCINATION; HUMAN; INCIDENCE; LEWY BODY; NAUSEA; NEUROPSYCHOLOGICAL TEST; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; QUALITY OF LIFE; RATING SCALE; REVIEW; RISK FACTOR; SYNCOPE; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 38149053638     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Aarsland D, Anderson K, Larsen JP, et al. 2003. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol, 60:387-92.
2. Aarsland D, Ballard CG, Halliday G. 2004. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol, 17:137-45.
3. Aarsland D, Perry R, Brown A, et al. 2005. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol, 58:773-6.
4. [APA] American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders (4th edn). Washington: APA.
5. Ballard C, Lane R, Barone P, et al. 2006. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract, 60:639-45.
6. Bohnen NI, Kaufer DI, Ivanco LS, et al. 2003. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol, 60:1745-8.
7. Brown RG, Marsden CD. 1984. How common is dementia in Parkinson's disease? Lancet, 2:1262-5.
8. Burn DJ, Rowan EN, Allan LM, et al. 2006. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry, 77:585-9.
9. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. 2006. International multicenter pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord, 21:916-23.
10. Cummings JL. 1988. Intellectual impairment in Parkinson's disease: clinical, pathological, and biochemical correlates. J Geriatr Psychiatry Neurol, 1:24-36.
11. de Lau LM, Schipper CM, Hofman A, et al. 2005. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neural, 62:1265-9.
12. Defer GL, Widner H, Marie RM, et al. 1999. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord, 14:572-84.
13. Emre M, Aarsland D, Albanese A, et al. 2004. Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine, 351:2509-18.
14. Enz A, Amstutz R, Bodekke H, et al. 1993. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res, 98:431-8.
15. Enz A, Bodekke H, Gray J, et al. 1991. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann N Y Acad Sci, 640:272-5.
16. Fernandez HH, Crucian GP, Okun MS, et al. 2005. Mild cognitive impairment in Parkinson's disease: the challenge and the promise. Neuropsychiatric Disease and Treatment, 1:37-50.
17. Fogelson N, Kogan E, Korczyn AD, et al. 2003. Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neural Scand, 107:252-5.
18. Fuchs GA, Gemende I, Herting B, et al. 2004. Dementia in idiopathic Parkinson's syndrome. J Neurol, 251 Suppl 6:VI/28-32.
19. Galvin JE, Pollack J, Morris JC. 2006. Clinical phenotype of Parkinson disease dementia. Neurology, 67:1605-11.
20. Geldmacher DS. 2005. The costbenefit to health plans of pharmacotherapy for Alzheimer's disease. Manag Care, 14:44-6, 49-52, 54-5.
21. Gibb WR, Lees AJ. 1988. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry, 51:745-52.
22. Giladi N, Shabtai H, Gurevich T, et al. 2003. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand, 108:368-73.
23. Gurevich TY, Shabtai H, Korczyn AD, et al. 2006. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. Mov Disord, 21:1663-6.
24. Harada CN, Shega JW, Sachs GA. 2005. Rivastigmine for dementia associated with Parkinson's disease. New Engl J Med, 352:13 87.
25. Hely MA, Morris JG, Reid WG, et al. 2005. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord, 20:190-9.
26. Hilker R, Thomas AV, Klein JC, et al. 2005. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology, 65:1716-22.
27. Hughes TA, Ross HF, Mindham RH, et al. 2004. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neural Scand, 110:118-23.
28. Leroi 1, Brandt J, Reich SG, et al. 2004. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry, 19:1-8.
29. Levy G. 2006. Dementia in Parkinson's disease challenges the "gold standard". Ann Neurol, 58:663-5.
30. Levy G, Schupf N, Tang MX, et al. 2002. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol, 51:722-9.
31. Mahler ME, Cummings JL. 1990. Alzheimer disease and the dementia of Parkinson disease: comparative investigations. Alzheimer Dis Assoc Disord, 4:133-49.
32. Marder KS, Tang MX, Cote L, et al. 1995. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol, 52:695-701.
33. McKeith I, Del Ser T, Spano P, et al. 2000. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet, 356(9247):2031-6.
34. McKeith IG, Dickson DW, Lowe J, et al. 2005. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology, 65:1963-72.
35. Molchan SE, Vitello B, Minichiello M, et al. 1991. Reciprocal changes in psychosis and mood after physostigmine in a patient with Alzheimer's disease [letter]. Arch Gen Psychiatry, 48:1113.
36. Miyasaki JM, Shannon K, Voon V, et al. 2006. Practice Parameter. evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66:996-1002.
37. Nasreddine ZS, Phillips NA, Bedirian V, et al. 2005. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool for Mild Cognitive Impairment. J Am Geriatr Soc, 53:695-9.
38. Noe E, Marder K, Bell KL, et al. 2004. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease dementia. Mov Disord, 19:60-7.
39. Padovani A, Costanzi C, Gilberti N, et al. 2006. Parkinson's disease and dementia. Neurol Sci, 27 Suppl 1:S40-3.
40. Parkinson J. An essay on the shaking palsy. London, England: Sherwood, Neely, and Jones. p 1817.
41. Perl DP, Olanow CW, Calne D. 1998. Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol, 44(3 Suppl 1):S19-31.
42. Pillon B. 2002. Neuropsychological assessment for management of patients with deep brain stimulation. Mov Disord, 17 Suppl 3: S116-22.
43. Poewe W, Wolters E, Emre M, et al. 2006. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord, 21:456-61.
44. Ravina B, Putt M, Siderowf A, et al. 2005, Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry, 76:934-9.
45. Reading PJ, Luce AK, McKeith IG, 2001. Rivastigmine in the treatment of Parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord, 16:1171-4.
46. Richard IH, Justus AW, Greig NH, et al. 2002. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharm, 25:296-9.
47. Rippon GA, Marder KS. 2005. Dementia in Parkinson's disease. Adv Neurol, 96:95-113.
48. Saint-Cyr JA, Trepanier LL, Kumar R, et al. 2000. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain, 123:2091-108.
49. Voon V, Kubu C, Krack P, et al. 2006. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord, 14:S305-27.
50. Wesnes KA, McKeith I, Edgar C, et al. 2005. Benefits of rivastigmine on attention in dementia associated with Parkinson's disease. Neurology, 65:1654-6.
51. Whitehouse P. 1987. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease. Adv Neurol, 45:393-7.
52. Willan AR, Goeree R, Pullenayegum EM, et al. 2006. Economic evaluation of rivastigmine in patients with Parkinson's disease dementia. Pharmacoeconomics, 24:93-106.